Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.

For more information, you can see as below;

http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201506&newsid=1931735&newslang=en

*We will update mite-disease. info including with this information.